| Budget Amount *help |
¥5,460,000 (Direct Cost: ¥4,200,000、Indirect Cost: ¥1,260,000)
Fiscal Year 2014: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
Fiscal Year 2013: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
Fiscal Year 2012: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
|
|---|
| Outline of Final Research Achievements |
Sepsis is known as systemic inflammatory response syndorome (SIRS) with symptoms such as hypercytokinemi. Now, it is need to improve the therapy of sepsis. To establish effective therapy of sepsis, we investigated a role of purinergic signaling on sepsis by using immune cells and sepsis model mice in this study. We found that activation of P2Y11 receptor by exocytic ATP release in macrophage is involved in production of pro-inflammatory cytokine. P2Y11 receptor antagonist suppressed an increase of cytokine in LPS-treated mice. On the other hand, we also found that activation of P2X7 receptor play an important role in sepsis, suggesting that P2Y11 and P2X7 receptor antagonists would become a novel candidate of sepsis therapy.
|
